Please assess the completion status of the following clinical trial:

Trial Title: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NB as defined by a) histopathology (confirmed by the MSKCC Department of Pathology), or b) BM metastases or MIBG-avid lesion(s) plus high urine catecholamine levels.~* High-risk NB as defined by risk-related treatment guidelines1 and the International NB Staging System,89 i.e., stage 4 with (any age) or without (\> or = to 18 months of age) MYCN amplification, MYCN-amplified stage 2 or stage 3 (any age), or MYCN-amplified stage 4S.~* The patients are in \>2nd CR/VGPR, including no measurable MIBG-avid soft tissue tumor assessable for response.~* Signed informed consent indicating awareness of the investigational nature of this program.~Exclusion Criteria:~* Creatinine \> 3.0 mg/dL~* ALT, AST and Alkaline Phosphatase \> 5.0 times the upper limit of normal~* Bilirubin \> 3.0 mg/dL~* Patients with grade 3 or higher toxicities (using the CTCAE v34.0) related to cardiac, neurological, pulmonary or gastrointestinal function as determined by physical exam. Patients must have normal blood pressure for age.~* Progressive disease~* History of allergy to mouse proteins~* Active life-threatening infection.~* Human anti-mouse antibody (HAMA) titer \>1000 Elisa units/ml.~* Inability to comply with protocol requirements.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid (Type: EXPERIMENTAL): This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).